ENDLOS-TURBO CALL - ELI LILLY & CO | Delayed Deutsche Boerse AG 02:34:24 2024-06-25 EDT | ||
| 50.79 EUR | -0.06% |
|
| Current month | +17.20% | ||
| 1 month | +18.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 50.79 | -0.06% |
| 24-06-24 | 50.82 | +1.01% |
| 24-06-21 | 50.31 | +0.48% |
| 24-06-20 | 50.07 | -1.79% |
| 24-06-19 | 50.98 | +0.85% |
Delayed Quote Deutsche Boerse AG
Last update June 25, 2024 at 02:34 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | DZ BANK |
| WKN | DJ0D7L |
| ISIN | DE000DJ0D7L8 |
| Date issued | 2023-03-15 |
| Strike | 347.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.11 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 51.94 € |
|---|---|
| Lowest since issue | 0.84 € |
| Spread | 0.24 € |
| Spread % | 0.47% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
890.1
USD
Average target price
860.5
USD
Spread / Average Target
-3.32%
- Stock Market
- Certificates
- Certificat
